Searched for
INSULIN PEN DEVICES
Price alone won't push weight-loss, diabetes drug semaglutide sales: DoctorsLeading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenma...- Zydus plans launch of semaglutide generic in reusable pen formZydus Lifesciences is set to launch a generic version of the weight-loss injection semaglutide next month. The drug will be available under...
- Novo Nordisk’s Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it worksNovo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy conta...
- Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other detailsNovo Nordisk has introduced its weight-loss drug, Wegovy, in India. This launch follows Eli Lilly's entry into the market. The company aims...
- Novo Nordisk to phase out key drug, insulin cos spot big biz opportunityNovo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the a...
- Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brandNovo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They ...
- Biocon's partner Mylan gets favourable ruling from US patent authority for 4 devices"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. Thi...
- Biocon, Mylan win US court ruling in favour of insulin GlargineUS District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insuli...
- In a first, syringe and needle manufacturers seek price capSyringes and needles are among the most commonly used devices which account for huge bills, and are being used by hospitals to fleece patie...
- How insulin therapy is proving to be a boon for type-1 diabeticsHowever, improper choice of injection site, technique including reuse of needles might lead to compromised outcomes.
- Diabetes can ruin your sex life: Quit smoking, follow these measuresAbout 25% of women and 50% of men with diabetes experience some kind of sexual problem or loss of sexual desire.
- Biocon bags Rs 460-crore contract from MalaysiaThe drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...
- Biocon Q2 net profit jumps 3-fold at Rs 306 croreThe consolidated revenue of Biocon was up by 11.38 per cent at Rs 861 crore during the quarter compared to Rs 773 crore in the year-ago per...
- Fourteen stocks in focus in Wednesday's tradeIndian markets are expected to trade higher. Here is a list of fourteen stocks which are likely to remain in focus today.
- Biocon opens facility to produce devices for insulin portfolioSpread over 10,000 square feet, the facility will manufacture pen like delivery devices for people with diabetes in India and other parts o...
- Hackathons move past innovation, engages in finding right talent for specific rolesHackathons, or hackfests, are moving beyond generic mainstream technologies such as Android and iOS, to specialised avenues.
- IoT hackathons, a growing culture in BengaluruBengaluru is certainly no stranger to hackathons, meet-ups for geeks to show-off by building technology solutions to specific problems.
- Sanofi to join hands with Apollo Hospitals for diabetes clinics rolloutApollo Sugar will be a part of Apollo Health & Lifestyle, the arm of Apollo that is into primary and secondary healthcare.
- Eli Lilly testing pricing model in IndiaThe Indian arm of Eli Lilly is attempting new drug pricing models here to ensure that its drugs can reach a large number of patients.
- NPPA’s price ceiling on insulin absurd, will encourage imports: Kiran Mazumdar-Shaw, BioconIn an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about NPPA’s price ceiling on insulin and its effects on Biocon.
Load More
